Analysts predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will announce $800,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Aclaris Therapeutics’ earnings, with the lowest sales estimate coming in at $600,000.00 and the highest estimate coming in at $1.00 million. The business is scheduled to report its next quarterly earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $800,000.00 for the current financial year, with estimates ranging from $680,000.00 to $1.68 million. For the next fiscal year, analysts expect that the firm will post sales of $19.57 million per share, with estimates ranging from $12.06 million to $28.00 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million.
Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Friday, December 15th. Finally, ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $39.20.
Hedge funds and other institutional investors have recently modified their holdings of the business. Citigroup Inc. increased its holdings in Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 2,726 shares during the period. Legal & General Group Plc increased its holdings in Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 2,605 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Aclaris Therapeutics during the 3rd quarter worth about $142,000. Voya Investment Management LLC purchased a new stake in Aclaris Therapeutics during the 2nd quarter worth about $247,000. Finally, Trexquant Investment LP purchased a new stake in Aclaris Therapeutics during the 3rd quarter worth about $247,000. Institutional investors own 92.02% of the company’s stock.
Aclaris Therapeutics (ACRS) traded up $0.44 during mid-day trading on Friday, hitting $24.63. The company had a trading volume of 177,537 shares, compared to its average volume of 427,609. The stock has a market cap of $759.47, a P/E ratio of -11.40 and a beta of 1.96. Aclaris Therapeutics has a 52-week low of $21.32 and a 52-week high of $33.25.
TRADEMARK VIOLATION WARNING: “$800,000.00 in Sales Expected for Aclaris Therapeutics Inc (ACRS) This Quarter” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/07/800000-00-in-sales-expected-for-aclaris-therapeutics-inc-acrs-this-quarter.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.